← 返回前沿论文

具有可编程信号活性的合成受体的计算设计用于增强肿瘤 T 细胞治疗

英文原题:Computational design of synthetic receptors with programmable signalling activity for enhanced cancer T cell therapy.

PubMed 2025/10/28(内容时间) Nat Biomed Eng Q1 · IF 26.3(JCR 2025)

研究概要

肿瘤微环境(TME)在肿瘤进展中起关键作用,TME 中的可溶性与细胞成分可限制 CAR-T 细胞的功能和持久性。

中文摘要

肿瘤微环境(TME)在肿瘤进展中发挥关键作用,其可溶性和细胞组分会限制CAR-T细胞功能和持续存在。由于合成蛋白受体的信号特性难以预测,通过嵌合受体靶向可溶性TME因子以增强工程化T细胞抗肿瘤应答的策略尚未得到广泛探索。本研究开发了一种计算蛋白质设计平台,可自下而上从头组装异构变构受体,使其具有可编程输入-输出行为:在T细胞中感知可溶性TME因子,并触发共刺激和细胞因子信号。这类受体称为肿瘤应答增强型TME感知转换受体(T-SenSER)。研究者构建了两组T-SenSER,分别靶向血管内皮生长因子(VEGF)或集落刺激因子1(CSF1),二者均在多种肿瘤中选择性富集。将CAR与T-SenSER共同导入人T细胞后,在肺癌和多发性骨髓瘤模型中可分别依赖VEGF或CSF1增强抗肿瘤应答。本研究为加速开发具有定制化感知和应答功能的合成生物传感器奠定了基础,可用于基础和转化细胞工程。

展开英文摘要原文

The tumour microenvironment (TME) plays a key role in tumour progression, and soluble and cellular TME components can limit CAR-T cell function and persistence. Targeting soluble TME factors to enhance anti-tumour responses of engineered T cells through chimeric receptors is not broadly explored owing to the unpredictable signalling characteristics of synthetic protein receptors. Here we develop a computational protein design platform for the de novo bottom-up assembly of allosteric receptors with programmable input-output behaviours that respond to soluble TME factors with co-stimulation and cytokine signals in T cells, called TME-sensing switch receptor for enhanced response to tumours (T-SenSER). We develop two sets of T-SenSERs targeting vascular endothelial growth factor (VEGF) or colony-stimulating factor 1 (CSF1) that are both selectively enriched in a variety of tumours. Combination of CAR and T-SenSER in human T cells enhances anti-tumour responses in models of lung cancer and multiple myeloma, in a VEGF- or CSF1-dependent manner. Our study sets the stage for the accelerated development of synthetic biosensors with custom-built sensing and responses for basic and translational cell engineering applications.

论文信息

作者
Rath JA、Rudden LSP、Nouraee N、Que TXY、Von Gunten C、Perez C、Birch F、Bhugowon Y
第一作者单位
Department of Oncology UNIL-CHUV, University Hospital Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.Switzerland
通讯作者单位
Department of Oncology UNIL-CHUV, University Hospital Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland. caroline.arber@unil.ch.Switzerland
期刊
Nature biomedical engineering2026 Apr
原文标识
PubMed 41152568 · DOI 10.1038/s41551-025-01532-3